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The purpose of this study was to classify selective oestrogen receptor modulators based on gene expression proﬁles
produced in breast cancer cells expressing either wtERa or mutant351ERa. In total, 54 microarray experiments were carried
out by using a commercially available Atlas cDNA Expression Arrays (Clontech), containing 588 cancer-related genes. Nine
sets of data were generated for each cell line following 24 h of treatment: expression data were obtained for cells treated
with vehicle EtOH (Control); with 10
79 or 10
78 M oestradiol; with 10
76 M 4-hydroxytamoxifen; with 10
76 M raloxifene;
with 10
76 M idoxifene, with 10
76 M EM 652, with 10
76 M GW 7604; with 5610
75 M resveratrol and with 10
76 M ICI
182,780. We developed a new algorithm ‘Expression Signatures’ to classify compounds on the basis of differential gene
expression proﬁles. We created dendrograms for each cell line, in which branches represent relationships between
compounds. Additionally, clustering analysis was performed using different subsets of genes to assess the robustness of the
analysis. In general, only small differences between gene expression proﬁles treated with compounds were observed with
correlation coefﬁcients ranged from 0.83 to 0.98. This observation may be explained by the use of the same cell context for
treatments with compounds that essentially belong to the same class of drugs with oestrogen receptors related mechanisms.
The most surprising observation was that ICI 182,780 clustered together with oestrodiol and raloxifene for cells expressing
wtERa and clustered together with EM 652 for cells expressing mutant351ERa. These data provide a rationale for a more
precise and elaborate study in which custom made oligonucleotide arrays can be used with comprehensive sets of genes
known to have consensus and putative oestrogen response elements in their promoter regions.
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Selective oestrogen receptor (ER) modulators (SERMs) are a new
class of drugs, which have a profound impact in breast cancer
treatment and prevention (Levenson and Jordan, 1999). Tamoxifen
is one of the most effective SERM for the treatment of ER positive
breast cancers; however, despite the initial favourable response to
tamoxifen therapy, eventually tumours become refractory to treat-
ment resulting in disease recurrence (Tonetti and Jordan, 1995).
Often these tumours will subsequently respond to alternative
hormonal therapy.
It is well known that there are mechanistic differences among
SERMs because following binding to ER each ligand induces a
distinct ER-ligand conformation, that is recognised distinctly by
the transcription machinery (Wijayaratne et al, 1999). It is, there-
fore, logical to assume that individual SERMs induce different gene
expression proﬁles. Identiﬁcation of additional SERMs, on the basis
of their differential gene expression proﬁles, could be useful in
predicting outcome of the second-line therapy.
Differential pharmacology of SERMs is best represented in
different tissues. Table 1 summarises the in vivo pharmacological
and/or therapeutic activities of compounds used in this study.
The mechanisms of oestrogen action by binding two speciﬁc intra-
cellular ERs (a and b) reviewed in (Nilsson et al, 2001). The anti-
oestrogen tamoxifen has oestrogenic activities in the bone, uterus
and the cardiovascular system (Bagdade et al, 1990; Ryan et al,
1991; Love et al, 1994; Barrett-Connor et al, 1999) and is an
anti-oestrogenic in the breast (Jordan, 2000; Morrow and Jordan,
2000). Raloxifene (Ral), on the other hand, has less oestrogenic
effects on uterus, but the same beneﬁcial effects on bone and lipid
metabolism (Delmas et al, 1997; Barrett-Connor et al, 1999; Cohen
et al, 2000) while it is an antagonist of oestrogen action in the
breast (Gottardis and Jordan, 1987; Cummings et al, 1999). Other
SERMs like idoxifene (Idox) (Chander et al, 1991; Nuttall et al,
1998), GW 5638 (Willson et al, 1994, 1997; Connor et al, 2001)
and EM 800 (Luo et al, 1998; Labrie et al, 1999; Martel et al,
2000) are different from tamoxifen and based on their activity in
the rodent uterus are more closely related to raloxifene. Resveratrol
(Res) does not formally belong to the SERM family, because it is a
phytoestrogen found in the plants (Jang et al, 1997), however Res
has similar in vivo characteristics to the SERMs (Mizutani et al,
2000; Bhat and Pezzuto, 2001; Wu et al, 2001). ICI 182,780
(ICI) is a pure anti-oestrogen with anti-oestrogenic activities in
almost all tissues, with no changes in serum lipids and on bone
density (Wakeling and Bowler, 1987; Wakeling et al, 1991; Lee et
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treatment of advanced breast carcinoma (Howell et al, 2000).
Although it is possible to determine quantitatively the expression
of thousands of genes in a single sample, there are signiﬁcant tech-
nical issues to address for a comparison of gene expression proﬁles
induced by a SERM-ER complex in different tissues. Cellular
heterogeneity of different tissues is one of the problems. An
approach to this issue would be to use a system in vitro to charac-
terise different compounds and their differential pharmacology. We
have developed a model system in vitro, in which some SERMs
demonstrate oestrogen-like activities while others remain anti-
oestrogenic (Levenson et al, 1997, 1998a,b,c, 2001; Levenson and
Jordan, 1998).
The goal of this study was to classify SERMs on the basis of gene
expression proﬁles of breast cancer cells expressing either wtERa
(D351) or mutant351ERa (D351Y) after exposure to SERMs for
24 h. To our knowledge this is the ﬁrst attempt to classify SERMs
using cDNA microarrays. We chose a well characterised model
system in vitro in which cellular machinery is adapted for ER-
nonmediated transcription of genes (MDA-MB-231 cells), and
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Compound Structure Oestrogen-like
effects
a
Anti-oestrogen-like
effects
Oestradiol
Tamoxifen
b
Raloxifene
Idoxifene
GW 5638
b
EM 800b
Resveratrol
Breast
Uterus
Bone
Lipid metabolism
Uterus
Bone
Lipid metabolism
Bone
Lipid metabolism
Breast
Breast
Uterus
Bone
Lipid metabolism
Bone
Lipid metabolism
Bone
Lipid metabolism
Bone
Lipid metabolism
Breast
Uterus
Breast
Uterus
Breast
Uterus
Breast
Uterus
Breast
Uterus
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aSummary is based on in vivo activities of compounds. bActive metabolites for tamoxifen (4OHT), GW 5638 (GW 7604) and EM
(EM652) were used in this study.
Table 1 Summary of oestrogen-like and anti-oestrogen-like activities of SERMs used in this study
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British Journal of Cancer (2002) 87(4), 449–456 ã 2002 Cancer Research UKoestrogen-responsiveness is restored by introduction of the ER gene
into cells. The D351Y mutation in ER, changes SERM-induced
transcriptional activities of endogenous gene expression (Levenson
et al, 1997, 1998b,c, 2001; Levenson and Jordan, 1998; MacGregor
Schafer et al, 1999) in these cells.
Different analytical tools have been proposed for analysing
microarray data (Eisen et al, 1998; Golub et al, 1999; Kalocsai
and Shams, 2001; Tamayo et al, 1999; Toronen et al, 1999; Bittner
et al, 2000). Our goal was to identify the gene expression proﬁles of
cells treated with the drug, compare the proﬁles from all samples
(cells treated with different drugs) and then cluster similar from
different proﬁles. We describe a new algorithm ‘Expression Signa-
tures’ for the classiﬁcation of compounds based on differential gene
expression proﬁles of cells treated with these compounds.
MATERIALS AND METHODS
Tissue culture
The cells stably expressing wtERa and mutant351ERa used in this
study were constructed from the ER-negative MDA-MB-231 human
breast cancer cells as described previously (Jiang and Jordan, 1992;
Catherinoetal,1995).ThelevelofERainbothcelllinesiscomparable
to the level of ERa in MCF-7 cells. Cells were maintained in phenol
red-free MEM with 5% charcoal-dextran treated calf serum, supple-
mented with 100 mgm l
71 streptomycin, 100 units ml
71 penicillin,
2m ML -glutamine, 6 ng ml
71 bovine insulin, 100 mM nonessential
amino acids, and 500 mgm l
71 G418. All of the tissue culture solu-
tions were from Life Technologies, Inc. (Gaithersburg, MD, USA).
Hormones
17-b Oestradiol (E2) and Res were purchased from Sigma Chemi-
cal Co. (St. Louis, MO, USA). 4-OHT, EM-652 and ICI 182,780
were gifts from Dr Alan Wakeling (ICI Pharmaceuticals Maccles-
ﬁeld, UK). Raloxifene was a generous gift from Eli Lilly Research
Laboratories (Indianapolis, IN, USA). GW 7604 was a generous gift
from Dr Timothy Willson (Glaxo Wellcome Inc., Durham, NC,
USA). Idoxifene was a gift from Smith Kline Beecham (Philadel-
phia, PA, USA). All compounds used in the experiments were
dissolved in 100% ethanol and added to the medium in 1:1000
dilutions for a ﬁnal ethanol concentration no higher than 0.2%.
cDNA array-based expression proﬁling
We used AtlasTM Human cDNA Expression Arrays (Clontech,
Palo Alto, CA, USA), containing cDNA fragments representing
588 known cancer-related genes and nine housekeeping genes. A
complete list of the 588 genes of the AtlasTM Human Expression
Array used can be accessed through the Internet at http://
www.clontech.com.
Total RNA was isolated using TRIZOL reagent (Gibco–BRL) as
described previously (Levenson et al, 1997). The preparation and
hybridisation of
32P-labelled cDNA from 5 mg of total RNA were
performed as described in the manufacturer’s protocol. The experi-
ments for each condition were conducted three times with at least
two sets of RNAs and two different membranes. The hybridised
membranes were exposed for 72–96 h at 7808C using BioMax
TranScreen HE Intensifying Screen (Kodak, Rochester, NY, USA).
Signal intensities at each cDNA spot were detected by phosphor-
image analysis using a Molecular Dynamic Storm phosphoimager
(Molecular Dynamics, Sunnyvale, CA, USA). Initial analysis was
performed using AtlasImageTM 1.5 software (Clontech). Following
background correction, each gene on the membrane was normal-
ised to a reference GAPDH then the signal intensity was
calculated for each spot on the array and reported in an Excel data-
base. For further analysis of the data (see below) ‘all to one’
normalisation was applied when all samples (treated with
compounds) were normalised to one sample (untreated control).
‘Expression signatures’ analysis
A new method for classiﬁcation of different compounds on the
basis of gene expression proﬁles entitled ‘expression signatures’
was developed by our group. The method involved the following
steps. Genes were reordered in the ascending order of their expres-
sion levels in the untreated samples. We denoted the expression of
a gene with number ‘i’ in reordered set as Ei, where sub-index ‘i’
corresponds to the gene number, and Ei means an expression level
of that gene. Therefore, Ej 4Ei for j 4i. Further, the data in gene
arrays obtained under the inﬂuence of compound R were arranged
in the same order, and were denoted as Ei
(R). We propose the
following formula to compute rescaled gene expressions Pi:
Pi  Log2Ei=Enorm  1 1
Enorm is normalizing coefﬁcient. In the present work, we adopted
the following expression for Enorm:E norm=Eref/Emin
1/2. We used
GAPDH as a reference (Eref), and Emin is the minimal level of
intensity identiﬁed in the experiments. If sets of Ei correspond to
the untreated sample, we get sets of Pi
(0) of scaled gene proﬁles;
for samples treated with compound R, we obtain Pi
(R). The formu-
la (1) has two important properties: (a) original expressions Ei=0
are transformed into rescaled Pi=0, and (b) for high Ei the formula
is asymptotically logarithmic with base 2. Next, we plot Pi
(R) for
each compound versus Pi
(0) of untreated sample. This is called
the ‘expression signature’ of the compound. Similarities or differ-
ences between gene expression proﬁles produced by compounds
R and Q can be calculated using Euclidian distance D [R,Q]:
DR;Q  1=niRi ÿ Qi
2
1=2 2
where n is total number of genes. Interpretation of the distances
and signatures allows grouping of the compounds on the basis of
gene expression proﬁles produced.
The intrinsic gene list that formed the basis for the classiﬁcation
was selected for each cell line to include those which showed good
reproducible expression data from each of the three experiments
performed for each compound and those which had intensity high-
er than 4000. This subset of genes for cells expressing wtERa was
represented by 87 genes and for those expressing mutant351 ERa
by 117 genes. (Complete data sets for expression proﬁles are avail-
able at http://www.math.mtu.edu/*igor/Gene_index.html.)
Cluster analysis
We extracted normalised expression data for cells expressing wtERa
from an Excel data base generated by AtlasImage
TM 1.5 software
(Clontech). The same criteria of reproducibility and accuracy were
applied to select subsets of genes from the 588 cDNAs on the array.
Clustering was performed using the subset of up-regulated genes after
treatment with compounds compared to the control untreated cells.
We applied a hierarchical clustering algorithm described by
Eisen et al (1998) and available as ‘Cluster and TreeView’ manual
at http://rana.stanford.edu/software. The results of this process
were two dendrograms, one for the compounds and one for the
genes. The dendrogram for the compounds is of interest for the
current study.
RESULTS
We identiﬁed gene expression proﬁles in MDA-MB-231 human
breast cancer cells transfected with either wtERa or mutant351ERa
following treatment with E2, SERMs (4OHT, Ral, Idox, GW, EM,
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 449–456Res) and pure anti-oestrogen ICI. In total, 54 microarray experi-
ments were carried out. Nine sets of data were generated for each
cell line following 24 h of treatment: gene expression proﬁle for cells
treated with vehicle EtOH (Control); with 10
79 or 10
78 M E2; with
10
76 M 4OHT; with 10
76 M Ral; with 10
76 M Idox, with 10
76 M
EM, with 10
76 M GW; with 5610
75 M Res and with 10
76 M
ICI. The concentrations of compounds for each cell line used in this
study have been determined previously (Levenson et al, 1997;
1998a,b,c, 2001) and the maximally effective dose for each
compound was chosen for the array experiments.
We developed a new algorithm ‘expression signatures’ (see
Materials and Methods) to classify compounds based on differen-
tial gene expression modulation. In contrast to the hierarchical
cluster analysis this method allows the use of raw normalised data
sets without any major modiﬁcation of the data. We ﬁrst consid-
ered the whole set of 588 genes represented on the array to
compare the ‘signatures’ of compound-treated cells. However,
based on our ﬁndings of unacceptable experimental variations
and artefacts produced by the microarray technology itself, we
searched for genes that were not inﬂuenced by the experimental
variations (see Materials and Methods). Figure 1A shows ‘expres-
sion signatures’ of cells expressing wtERa treated with different
compounds for 24 h. Interpretation of the signatures on basis of
calculated ‘distances’ between the compounds showed similarities
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Figure 1 Expression signatures of cells treated with different compounds (E2, SERMs and ICI) versus the untreated control cells are shown. Eighty-seven
selected genes were used to create ‘Signatures’ for cells expressing wtERa (A) and dendrogram representing similarities in the expression patterns of cells
treated with different compounds were created from ‘expression signatures’ on the basis of data from distance metric and correlation coefﬁcients (B). The
branching patterns in the resulting dendrogram organised the compounds into three main groups: E2:Ral:ICI; 4OHT:GW; and Res:Idox: EM. Normalised
values for selected subset of genes were used for all manipulations. The values of normalised adjusted intensities representing levels of expressions of the
vehicle-treated control (X-axis) and the compound-treated (Y-axis) cells are shown for A.
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The resulting dendrogram for wtERa (Figure 1B) produced with a
selected subset of genes (87 genes) (see Materials and Methods),
resembled closely the dendrogram with all 588 genes (data not
shown). Surprisingly, E2, Ral and ICI grouped together, the next
closest is the group containing 4OHT and GW, whereas Res, Idox
and EM were on the most distant dendrogram branches. This
means that EM had lower correlation to the Control untreated
cells, whereas E2 had the highest correlation to the untreated cells.
When 117 selected groups of genes were used for ‘expression signa-
tures’ of cells expressing mutant351ERa, the resulting dendrogram
(Figure 2A,B) showed slightly different branching patterns. This
time the most distant branches from the E2, 4OHT and Ral group
was the GW, Idox and Res group.
The hierarchical clustering (Eisen et al, 1998) is often used
as a multivariate technique to ﬁnd groups of genes with simi-
lar expression proﬁles across a number of experiments and to
group the experimental samples according to the similarities in
their overall patterns of gene expression. This method was
successfully applied for tumour, tissue or cancer cell line clas-
siﬁcation purposes (Ben-Dor et al, 2000; Perou et al, 2000;
Ross et al, 2000; Gruvberger et al, 2001; Sorlie et al, 2001;
Welsh et al, 2001). To examine the robustness of the observed
clustering patterns by ‘Expression signatures’, hierarchical clus-
ter analysis (see Materials and Methods) was performed by
using subsets of up-regulated genes for each of seven experi-
mental conditions for cells expressing wtERa (Figure 3).
Once again, E2, Ral and ICI clustered together while cells trea-
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Figure 2 Expression signatures of cells treated with different compounds (E2, SERMs and ICI) versus the untreated control cells are shown. One hundred
and 17 selected genes were used to create ‘Signatures’ for cells expressing mutant351ERa (D351Y) (A) and dendrogram representing similarities in the
expression patterns of cells treated with different compounds were created from ‘expression signatures’ on the basis of data from distance metric and
correlation coefﬁcients (B). The branching patterns in the resulting dendrogram organised the compounds into three main groups: E2:4OHT:Ral; ICI:EM;
and GW:Idox: Res. Normalised values for selected subset of genes were used for all manipulations. The values of normalised adjusted intensities represent-
ing levels of expressions of the vehicle-treated control (X-axis) and the compound-treated (Y-axis) cells are shown for A.
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of the dendrogram.
Therefore, this data suggests that the classiﬁcation of SERMs is
relatively robust with E2, Ral and ICI staying together in the same
cluster when using different sets of selected genes for analysis.
DISCUSSION
The biological effects of oestrogen and SERMs in breast cancer are
mediated by the ER, a transcriptional regulator that controls the
pattern of gene expression. The crystal structures of the ligand
binding domain (LBD) of wtERa with agonists (E2 and DES)
and antagonists (Ral and 4OHT) (Brzozowski et al, 1997; Shiau
et al, 1998) conﬁrmed the central role of the ligand in modulating
ER conformation. It is now clear that each ligand upon binding,
induces unique structural alterations within the ER, changing its
conformation and its transcriptional activity. This means that
subsequent gene expression results from the ER-SERM complex
activating different, but complementary signal transduction path-
ways.
Because the actual mechanism that leads to differences of ﬁnal
phenotype depend not on single genes but on a global expression
pattern, we used cDNA Atlas Arrays to evaluate gene expression
proﬁles after activation of ERa by different ligands. It has been
previously shown that it is possible to group SERMs based on
differences and similarities in the pattern of gene expression
changes that they produced (Zajchowski et al, 2000). The authors
evaluated 24 gene per cell combinations comprising 10 different
known oestrogen-responsive genes in eight cell lines representing
four cell types. The aim of this study was to examine SERMs on
the basis of gene expression proﬁles using cDNA microarrays in
breast cancer cells known to elicit various oestrogenic responses
to different compounds.
It is very important to emphasise that in general the differences
between gene expression proﬁles treated with different compounds
were very small with correlation coefﬁcients ranging from 0.83 to
0.98. Our results reﬂect several limitations of this approach: (i)
we treat the same cell line (not a different cell line from different
origin) with compounds, so the differences are already very limited;
(ii) all these compounds (except ICI) belong to one class of drugs
(SERMs) that function through the ER, i.e. have similar mechan-
ism of action; and (iii) very small amount of all human genes
are represented on the arrays used. By analogy, when 20 of the
tumours were sampled before and after chemotherapy (Perou et
al, 2000) clustering analysis indicated a high degree of similarity
within samples derived from the same patient compared with those
from different patients. As a consequence, for tumour classiﬁca-
tion, Sorlie et al (2001) have used the list of genes to include
those with signiﬁcantly greater variation in expression between
different tumours than between paired samples from the same
tumour.
Our previous classiﬁcation of SERMs in these two cell lines was
based on one single marker of E2-responsiveness in these breast
cancer cells: E2 and 4OHT produced oestrogenic effects on the
activation of TGFa mRNA in cell expressing wtERa whereas Ral
and ICI were anti-oestrogens (Levenson et al, 1998b). With the
mutant receptor, Ral became oestrogenic as well (Levenson et al,
1997; Levenson and Jordan, 1998). These observations were extre-
mely important for understanding SERM action once X-ray
crystallography of the LBD of ERa with Ral and 4OHT was deter-
mined (Brzozowski et al, 1997; Shiau et al, 1998). Resveratrol had
the same effects on growth and expression of selected target genes
as E2 in both cell lines (Levenson, unpublished data). Both GW
and EM, on the other hand, showed similar effect as Ral with
D351 but were weakly oestrogenic with mutant D351Y ER
(MacGregor Schafer et al, 1999; Bentrem et al, 2001; Levenson et
al, 2001). It is hard to predict what impact on classiﬁcation of
SERMs would TGFa have, being just one gene out of 588 cDNA
spotted on the arrays, but because the expression of TGFa in all
membranes was at background levels, it was not considered at
all. This is concern with the technology. Despite this major limita-
tion we proceeded with a global analysis of results.
The most unexpected result was the fact that E2 grouped with
Ral and ICI in cells expressing wtERa. With presumed mechanism
of action for pure anti-oestrogen ICI, we expected ICI to appear at
the most distant branches of dendrogram from E2. The mode of
action of ICI recently summarised by Howell et al (2000) is that
ICI binds to ER with afﬁnity similar to that of E2, triggers rapid
degradation of ER, therefore there is a reduced rate of dimerisation
and nuclear localisation of ICI-ER complex with reduced binding
of the complex to oestrogen response elements (EREs). There is
no precise molecular description of those events, but obviously
reduced rate of ER-ICI complex and different conformational
changes in the dimmer inﬂuence various protein–protein interac-
tions in the transcriptional complex with subsequent transcription
of non-ER-mediated genes as well. Although the mode of action of
E2, Ral and ICI is different in terms of direct activation of E2-
responsive target genes with EREs (Howell et al, 2000), it might
be more similar in terms of transcription of other genes. It is
known that differences in ERE sequence also impact ER binding
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Figure 3 Gene expression patterns of cells expressing wtER related to
treatment with compounds (E2, SERMs and ICI). Two-dimensional hier-
archical clustering was applied to up-regulated subset of expression data
from a total of 588 cDNAs measured across seven different treatments.
A cluster dendrogram representing the hierarchical relationships between
gene expression proﬁles of cells (vertically) and compounds (horizontally)
was then generated. Colour-coded gene expression values for genes are
shown. The colour reﬂects the mean-adjusted expression level of the gene:
black is the mean, red is greater than the mean and green is less than the
mean.
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with ‘direct binding’ to the consensus ERE and ‘tethering’ mechan-
ism where ER interacts with another DNA-bound transcription
factor (i.e. Sp1, Ap-1) to initiate responsiveness of other target
genes (Klinge, 2001; Nilsson et al, 2001). Overall, if we consider
that (1) the level of ER protein goes down with E2, Ral and ICI
treatments in these cells (Levenson et al, 1998c; Liu et al, 2001)
and (2) the Atlas Arrays we used were spotted with PCR-ampliﬁed
cDNAs for 588 cancer-related genes with a very few E2-responsive
genes with putative EREs in their promoter regions, it is fair to say
that we are only detecting changes in non-ER-mediated genes.
Among E2-responsive genes were TGFa, VEGF, BRCA1 on the
array. We were surprised to ﬁnd that ligand-enhanced activation
of these genes was only background and we could not obtain
signiﬁcant variations in expression among SERMs-treated cells.
Clearly, future ventures to discover signal transduction pathways
must employ targeted array technology. Custom build gene arrays
speciﬁcally designed to address the cell cycle, apoptosis and angio-
genesis and replete with oestrogen-responsive genes may be the
only way to address mechanistic questions.
Finally, we were interested to observe that SERMs up-regulated
genes compared to control untreated cells in cells expressing D351
(Figure 1A) whereas in contrast, SERMs down-regulated genes in
cells expressing mutant D351Y ER (Figure 2A). The fact that the
ER is known to cause a repressive action with oestrogen in trans-
fectants (Levenson and Jordan, 1994) that is entirely opposite from
the actions of oestrogen in nature, suggests that SERMs are doing
the same with the D351Y ER where responses are more oestrogen-
like. Less complex cell systems should be addressed in the future.
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